GlassScriptPhysician profile
Aaron M Vanwagnen
NPI 1245305044
$2,382.71
in general payments reported to CMS, 2019-2025
24 companies · $947 in 2025
The $947 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $175 · 2021: $17.33 · 2024: $225 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $546.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $327.17 | 2019-2025 | |
| Amgen INC. | $245.58 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $194.14 | 2019-2025 | |
| Lilly USA, LLC | $180.17 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $142.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $137.14 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $112.65 | 2025 | Neffy |
| E.R. Squibb & Sons, L.L.C. | $88.15 | 2019-2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $79.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $42.74 | 2019 | |
| Merck Sharp & Dohme LLC | $42.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.88 | 2019 | |
| Amarin Pharma, INC. | $27.90 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.30 | 2024 | |
| Horizon Therapeutics Plc | $18.51 | 2019 | |
| Glaxosmithkline, LLC. | $18.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.22 | 2020 | |
| Radius Health, INC. | $16.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.26 | 2019 | |
| Indivior INC. | $13.39 | 2024 | Sublocade |
| Ultragenyx Pharmaceutical INC. | $12.76 | 2019 | |
| Sanofi Pasteur INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Vanwagnen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.